S850 SAFETY AND EFFICACY OF AN ANTI‐FCRN ANTIBODY, ROZANOLIXIZUMAB, IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF A PHASE II, MULTIPLE‐DOSE STUDY | Publicación